Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy

British Journal of Pharmacology

Volumn 168, Issue 8, 2013, Pages 1794-1807

  Althurwi, Hassan N ^a   Tse, Mandy M Y ^a   Abdelhamid, Ghada ^a   Zordoky, Beshay N M ^a   Hammock, Bruce D ^b   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiac hypertrophy; cytochrome P450; Isoprenaline (isoproterenol); soluble epoxide hydrolase inhibitor; TUPS

Indexed keywords

1 (1 METHANESULFONYL PIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXY PHENYL)UREA; ARACHIDONIC ACID; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYTOCHROME P450; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ISOPRENALINE; PROCOLLAGEN; UNCLASSIFIED DRUG; 1-(1-METHANESULFONYLPIPERIDIN-4-YL)-3-(4-TRIFLUOROMETHOXYPHENYL)UREA; CARBANILAMIDE DERIVATIVE; CARDIOTONIC AGENT; EPHX2 PROTEIN, RAT; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYP GENE; CYP1A1 GENE; CYP1B1 GENE; CYP2B1 GENE; CYP2B2 GENE; CYP4A3 GENE; CYP4F4 GENE; DRUG ACTIVITY; DRUG EFFICACY; FATTY ACID METABOLISM; GENE EXPRESSION; GENE INDUCTION; HEART VENTRICLE HYPERTROPHY; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CARDIOMEGALY; CELL LINE; CHEMICALLY INDUCED; DRUG ANTAGONISM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART; HUMAN; KIDNEY; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BODY WEIGHT; CARDIOMEGALY; CARDIOTONIC AGENTS; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ANTAGONISM; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION; HEART; HUMANS; ISOPROTERENOL; KIDNEY; LIVER; NATRIURETIC PEPTIDE, BRAIN; PHENYLUREA COMPOUNDS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84875411759     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12066     Document Type: Article

References (62)

1. Aboutabl ME, Zordoky BN, El-Kadi AO, (2009). 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158: 1808-1819.
2. Aboutabl ME, Zordoky BN, Hammock BD, El-Kadi AO, (2011). Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J Cardiovasc Pharmacol 57: 273-281.
3. Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, et al. (2009). Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A 106: 564-569.
4. Anwar-Mohamed A, El-Sherbeni AA, Kim SH, Althurwi HN, Zordoky BN, El-Kadi AO, (2012). Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart. Xenobiotica 42: 1235-1247.
5. Baldwin SJ, Bramhall JL, Ashby CA, Yue L, Murdock PR, Hood SR, et al. (2006). Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab Dispos 34: 1063-1069.
6. Barakat MM, El-Kadi AO, du Souich P, (2001). L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci 69: 1559-1571.
7. Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM, (2009). Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 46: 67-74.
8. Bleicher KB, Pippert TR, Glaab WE, Skopek TR, Sina JF, Umbenhauer DR, (2001). Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A. J Biochem Mol Toxicol 15: 133-142.
9. Bui AL, Horwich TB, Fonarow GC, (2011). Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8: 30-41.
10. Carreno JE, Apablaza F, Ocaranza MP, Jalil JE, (2006). [Cardiac hypertrophy: molecular and cellular events]. Rev Esp Cardiol 59: 473-486.
11. Chabova VC, Kramer HJ, Vaneckova I, Vernerova Z, Eis V, Tesar V, et al. (2007). Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol 47: 145-159.
12. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD, (2007). The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50: 225-237.
13. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB, (2004). Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32: 840-847.
14. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, et al. (2007). Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35: 682-688.
15. Elbekai RH, El-Kadi AO, (2006). Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112: 564-587.
16. Gharavi N, El-Kadi AO, (2005). tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand. Drug Metab Dispos 33: 365-372.
17. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, et al. (2005). Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 313: 943-951.
18. Hirasawa F, Kawagoe M, Arany S, Koizumi Y, Ueno Y, Sugiyama T, (2005). Styrene monomer primarily induces CYP2B1 mRNA in rat liver. Xenobiotica 35: 1089-1099.
19. Imig JD, Hammock BD, (2009). Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794-805.
20. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD, (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2 Pt 2): 690-694.
21. Jennings BL, Sahan-Firat S, Estes AM, Das K, Farjana N, Fang XR, et al. (2010). Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension 56: 667-674.
22. Kalsotra A, Anakk S, Boehme CL, Strobel HW, (2002). Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab Dispos 30: 1022-1028.
23. Karara A, Dishman E, Falck JR, Capdevila JH, (1991). Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem 266: 7561-7569.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
25. Kroetz DL, Xu F, (2005). Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 45: 413-438.
26. Kunos G, Robertson B, Kan WH, Preiksaitis H, Mucci L, (1978). Adrenergic reactivity of the myocardium in hypertension. Life Sci 22: 847-854.
27. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. (2002). Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106: 130-135.
28. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB, (1994). Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90: 1786-1793.
29. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. (2002). Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397-1402.
30. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
32. Lu T, Ye D, Wang X, Seubert JM, Graves JP, Bradbury JA, et al. (2006). Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol 575 (Pt 2): 627-644.
33. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, et al. (2008). Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40: 529-537.
35. Morisseau C, Hammock BD, (2005). Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45: 311-333.
36. Morisseau C, Hammock BD, (2007). Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protocol Toxico 33: 1-18.
37. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, et al. (1999). Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A 96: 8849-8854.
38. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E, (1995). Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13: 1091-1095.
39. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, Campbell WB, (2001). Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem 298: 327-336.
40. O'Connell JB, (2000). The economic burden of heart failure. Clin Cardiol 23 (3 Suppl.): III6-II10.
41. Rollin R, Mediero A, Fernandez-Cruz A, Fernandez-Durango R, (2005). Downregulation of the atrial natriuretic peptide/natriuretic peptide receptor-C system in the early stages of diabetic retinopathy in the rat. Mol Vis 11: 216-224.
42. Roman RJ, (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185.
43. Sellers KW, Sun C, Diez-Freire C, Waki H, Morisseau C, Falck JR, et al. (2005). Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J 19: 626-628.
44. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, et al. (2004). Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95: 506-514.
45. Soppa GK, Lee J, Stagg MA, Felkin LE, Barton PJ, Siedlecka U, et al. (2008). Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 77: 695-706.
46. Spector AA, Fang X, Snyder GD, Weintraub NL, (2004). Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43: 55-90.
47. Thum T, Borlak J, (2000a). Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br J Pharmacol 130: 1745-1752.
48. Thum T, Borlak J, (2000b). Gene expression in distinct regions of the heart. Lancet 355: 979-983.
49. Thum T, Borlak J, (2002). Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16: 1537-1549.
50. Tsai HJ, Hwang SH, Morisseau C, Yang J, Jones PD, Kasagami T, et al. (2010). Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci 40: 222-238.
51. Vakili BA, Okin PM, Devereux RB, (2001). Prognostic implications of left ventricular hypertrophy. Am Heart J 141: 334-341.
52. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. (1998). Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97: 48-54.
53. Wang MH, Stec DE, Balazy M, Mastyugin V, Yang CS, Roman RJ, et al. (1996). Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-hydroxylation and 11,12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 336: 240-250.
54. Wang MH, Guan H, Nguyen X, Zand BA, Nasjletti A, Laniado-Schwartzman M, (1999). Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol 276 (2 Pt 2): F246-F253.
55. Wauthier V, Verbeeck RK, Calderon PB, (2007). The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem 14: 745-757.
56. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, et al. (2006). Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103: 18733-18738.
57. Zeldin DC, DuBois RN, Falck JR, Capdevila JH, (1995). Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 322: 76-86.
58. Zordoky BN, El-Kadi AO, (2007). H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56: 317-322.
59. Zordoky BN, El-Kadi AO, (2008). Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 9: 122-128.
60. Zordoky BN, El-Kadi AO, (2010). Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 125: 446-463.
61. Zordoky BN, Aboutabl ME, El-Kadi AO, (2008). Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol- induced cardiac hypertrophy in rats. Drug Metab Dispos 36: 2277-2286.
62. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO, (2011). Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos 39: 1440-1450.